Cerestat

Pricing Availability   Qty

Save up to 40% on RUO Reagents with BIOSPRING24 (see details)

Description: Potent and noncompetitive NMDA antagonist
Alternative Names: CNS 1102
Chemical Name: N-(3-Ethylphenyl)-N-methyl-N'-1-naphthalenylguanidine hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (6)

Biological Activity for Cerestat

Cerestat is a potent and noncompetitive NMDA receptor antagonist (IC50 = 36 nM). Exhibits >70-fold selectivity for NMDA receptor over σ receptor. Neuroprotective in a rat model of focal ischemia.

Technical Data for Cerestat

M. Wt 339.86
Formula C20H21N3.HCl
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 137160-11-3
PubChem ID 60839
InChI Key CKAKVKWRMCAYJD-UHFFFAOYSA-N
Smiles N=C(N(C)C3=CC=CC(CC)=C3)NC1=C2C(C=CC=C2)=CC=C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Cerestat

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 16.99 50
DMSO 33.99 100

Preparing Stock Solutions for Cerestat

The following data is based on the product molecular weight 339.86. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.94 mL 14.71 mL 29.42 mL
5 mM 0.59 mL 2.94 mL 5.88 mL
10 mM 0.29 mL 1.47 mL 2.94 mL
50 mM 0.06 mL 0.29 mL 0.59 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

References for Cerestat

References are publications that support the biological activity of the product.

Reddy et al (1994) Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist. J.Med.Chem. 37 260 PMID: 8295213

Schäbitz et al (2000) The N-MthD.-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke 31 1709 PMID: 10884477


If you know of a relevant reference for Cerestat, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: Cerestat, Cerestat supplier, CNS1102, potent, noncompetitive, NMDA, receptors, antagonists, selective, neuroprotection, neuroprotective, ischemia, stroke, CNS, 1102, Receptors, 4492, Tocris Bioscience

Citations for Cerestat

Citations are publications that use Tocris products.

Currently there are no citations for Cerestat. Do you know of a great paper that uses Cerestat from Tocris? Please let us know.

Reviews for Cerestat

There are currently no reviews for this product. Be the first to review Cerestat and earn rewards!

Have you used Cerestat?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory Poster

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.